Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Swedish Orphan Biovitrum AB (publ)
  6. News
  7. Summary
    SOBI   SE0000872095

SWEDISH ORPHAN BIOVITRUM AB (PUBL)

(SOBI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Advent International Corporation and GIC Special Investments Pte. Ltd. cancelled the acquisition of Swedish Orphan Biovitrum AB (OM:SOBI) from Investor AB (OM:INVE A), AP Fonden 4 and others.

12/03/2021 EST

Advent International Corporation and GIC Special Investments Pte. Ltd. made an offer to acquire Swedish Orphan Biovitrum AB (publ) (OM:SOBI) from Investor AB (publ) (OM:INVE A), AP Fonden 4 and others for SEK 69.4 billion on September 1, 2021. Under the transaction, Offerors will acquire 295,144,629 SOBI shares at a price of SEK 235 per share in cash. The intention of the Offerors is that SOBI's existing Chief Executive Officer, Guido Oelkers, will remain Chief Executive Officer of SOBI following completion of the Offer. The financing of the transaction is done in combination of funds available pursuant to equity commitments from Advent and Aurora and debt financing committed to be provided by certain banks and credit funds. Offerors to promote a de-listing of Sobi's shares from Nasdaq Stockholm after the completion of Offer. Completion of the Offer is conditional upon, amongst other things, Offerors becoming the owner of more than 90% of the total number of shares in SOBI and the receipt of all necessary regulatory, governmental or similar clearances, approvals and decisions, including from competition authorities. Compulsory acquisition can be launched when 90% or more acceptances are received. Transaction requires customary merger control approval in European union, Russia, Turkey and US. Based on the opinion from Danske Bank, the board of SOBI believes that Offer is fair and unanimously recommends that SOBI shareholders accept the Offer. Investor AB and AP Fonden 4, which have shareholdings in SOBI representing approximately 36.45% and 6.96%, respectively, of the total number of shares and votes in SOBI have undertaken to accept the Offer and irrevocable undertakings have been received. The Board of SOBI permitted Offerors to carry out a confirmatory due diligence review of SOBI in connection with the preparation of the Offer. As on September 21, 2021, The offer document relating to the Offer has been approved and registered by the Swedish Financial Supervisory Authority. As on October 7, 2021, Advent International has?received?unconditional?approval?by the European Commission (EC) for acquisition of Orphan Biovitrum. As of October 8, 2021, Offeror has received the necessary competition clearances from the Turkish Competition Authority and the waiting period under the US Hart-Scott-Rodino Act has now expired. Competition clearance from the Russian Federal Antimonopoly Service is still pending. The?transaction, which was examined under a normal review procedure, does not cause competition concerns on account of the parties'?limited?position in all markets where horizontal or vertical overlaps were identified, the EU antitrust regulator said. The EC has delivered its decision in advance of the stipulated October 19 deadline. Offer has received competition clearance from the Russian Federal Antimonopoly Service, as well as all necessary clearances or confirmations that clearances are not required under applicable foreign direct investment legislation. This means that Agnafit Bidco has obtained all necessary regulatory, governmental or similar clearances, approvals, decisions and other actions from authorities or similar, including from competition authorities. As of November 8, 2021, Offerors have received an acceptance in respect of 250,238,815 shares of SOBI corresponding to approximately 84.8%. The acceptance period of the Offer is expected to commence on or around September 22, 2021 and expire on or around October 21, 2021, subject to any extensions. As of October 25, 2021, offer is extended to November 4, 2021. Offerors have decided to further extend the acceptance period of Offer to November 12, 2021. Offerors reserves the right to further extend the acceptance period for the Offer. As on November 23, 2021, Agnafit Bidco has now further extend the acceptance period for the Offer until December 1, 2021. Morgan Stanley & Co. International plc acted as financial advisor and Mannheimer Swartling Advokatbyr? AB acted as legal advisor to Swedish Orphan Biovitrum AB. Danske Bank A/S, Danmark,Sverige Filial acted as fairness opinion provider to the board of SOBI. Barclays PLC (LSE:BARC) served as a financial advisor for Advent. J.P. Morgan Securities Plc, Evercore Partners International LLP, Royal Bank of Canada (TSX:RY) and Skandinaviska Enskilda Banken AB (publ) (OM:SEB A) served as a financial advisor for Advent International and GIC Special Investments. Deutsche Bank Securities Inc. acted as financial advisor to Advent International Corporation. Pontus Enquist of Roschier Advokatbyr? Ab and Jonathan Wood, Murray Cox, Max Oppenheimer, Nitin Konchady, Lewis Blakey, Jenine Hulsmann, Neil Rigby and Nafees Saeed of Weil, Gotshal & Manges (London) Llp and Nafees Saeed and Elizabeth S. Weiswasser of Weil, Gotshal & Manges LLP acted as legal advisors to Advent International Corporation and GIC Special Investments. Linklaters LLP acted as legal advisor to GIC Special Investments Pte. Ltd. UBS AG, London Branch acted as financial advisor to Advent International Corporation. Jefferies Financial Group Inc. acted as financial advisor to Advent International Corporation. Advent International Corporation and GIC Special Investments Pte. Ltd. cancelled the acquisition of Swedish Orphan Biovitrum AB (publ) (OM:SOBI) from Investor AB (publ) (OM:INVE A), AP Fonden 4 and others on December 3, 2021.


ę S&P Capital IQ 2021
All news about SWEDISH ORPHAN BIOVITRUM AB (PUBL)
01/11Avalo Therapeutics Appoints Chief Commercial Officer
MT
2021Swedish Orphan Biovitrum Gets Positive Opinion From European Medicines Agency For COVID..
MT
2021Kineret« (anakinra) receives positive opinion from the CHMP for treatment of patients w..
AQ
2021Kineret« Receives Positive Opinion from the Committee for Medicinal Products for Human ..
CI
2021Swedish Orphan Biovitrum, Apellis Pharmaceuticals Win European Regulatory Nod For Blood..
MT
2021Apellis Pharmaceuticals Receives Approval From European Commission for Aspaveli
MT
2021Aspaveli« (pegcetacoplan) approved in EU as orphan drug for treatment of PNH
AQ
2021Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB Announce EU Approval of A..
CI
2021Swedish Orphan Biovitrum's Rare Blood Disease Therapy Achieves Haemoglobin Normalizatio..
MT
2021Apellis Pharmaceuticals Reports 46% Hemoglobin Normalization in Broad Paroxysmal Noctur..
MT
More news
Analyst Recommendations on SWEDISH ORPHAN BIOVITRUM AB (PUBL)
More recommendations
Financials
Sales 2021 15 226 M 1 656 M 1 656 M
Net income 2021 2 424 M 264 M 264 M
Net Debt 2021 8 958 M 974 M 974 M
P/E ratio 2021 22,4x
Yield 2021 -
Capitalization 54 070 M 5 891 M 5 880 M
EV / Sales 2021 4,14x
EV / Sales 2022 3,70x
Nbr of Employees 1 532
Free-Float 59,5%
Chart SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Duration : Period :
Swedish Orphan Biovitrum AB (publ) Technical Analysis Chart | SOBI | SE0000872095 | MarketScreener
Technical analysis trends SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 183,20 SEK
Average target price 198,88 SEK
Spread / Average Target 8,56%
EPS Revisions
Managers and Directors
Guido Oelkers President & Chief Executive Officer
Henrik Stenqvist Chief Financial Officer
Sven Hňkan Bj÷rklund Chairman
Anne Marie de Jonge Schuermans Head-Technical Operations & Senior Vice President
Sven Anders Ullman Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
SWEDISH ORPHAN BIOVITRUM AB (PUBL)-1.03%5 891
CSL LIMITED-9.01%91 245
WUXI BIOLOGICS (CAYMAN) INC.-3.19%48 492
SAMSUNG BIOLOGICS CO.,LTD.-9.41%45 433
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-8.09%32 393